Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.62 |
| ▸ | NPY1R | P25929 | 9/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.62 |
| ▸ | NPY2R | P49146 | 5/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Kyotorphin SCHEMBL2889815 | 1.00 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2R | |
| Kyotorphin SCHEMBL248288 | 1.00 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2R | |
| D[-Arg-2]Kyotorphan Acetate SCHEMBL29780328 | 1.00 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30198606 | 0.98 | NPY4R (0.66) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31155494 | 0.97 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29613396 | 0.97 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31729537 | 0.96 | NPY4R (0.69) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31575310 | 0.95 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13563452 | 0.95 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL18951657 | 0.95 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 637 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747264-A1 | MICELLAR BIOACTIVE COLLAGEN-STIMULATING LIPOPEPTIDE | University of Reading (GB) | 2026-05-27 | — | — | EP | claimed |
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | claimed |
| WO-2026088246-A1 | METHOD FOR PRODUCING LOW-MOLECULAR-WEIGHT COMPOUND | ＮＴＴ株式会社 | 2026-04-30 | — | — | WO | claimed |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | PHEON THERAPEUTICS LTD (GB) | 2026-01-29 | — | — | US | claimed |
| EP-4594520-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2025-08-06 | — | — | EP | claimed |
| WO-2025149667-A1 | ANTIBODY DRUG CONJUGATES AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2025-07-17 | — | — | WO | claimed |
| EP-4585606-A1 | OLIGOPEPTIDE AND USE AND COMPOSITION THEREOF | Buddhist Tzu Chi Medical Foundation (TW) | 2025-07-16 | — | — | EP | claimed |
| WO-2025120085-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | WO | claimed |
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | US | claimed |
| EP-4554623-A1 | ANTIBODY DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | Pheon Therapeutics Ltd (GB) | 2025-05-21 | — | — | EP | claimed |
| US-20020110525-A1 | Modulated release particles for lung delivery | KOS LIFE SCIENCES, INC. | 2002-08-15 | — | — | US | claimed |
| WO-2002005785-A1 | MODULATED RELEASE THERAPEUTIC AEROSOLS | AEROPHARM TECHNOLOGY INCORPORATED (US) | 2002-01-24 | — | — | WO | claimed |
| WO-2001082980-A1 | A MEDICINAL AEROSOL FORMULATION | AEROPHARM TECHNOLOGY, INC. (US) | 2001-11-08 | — | — | WO | claimed |
| WO-2001082868-A2 | A MEDICINAL AEROSOL FORMULATION | AEROPHARM TECHNOLOGY, INC. (US) | 2001-11-08 | — | — | WO | claimed |
| WO-2001082873-A2 | A MEDICINAL AEROSOL FORMULATION | AEROPHARM TECHNOLOGY, INC. (US) | 2001-11-08 | — | — | WO | claimed |
| WO-2001060420-A1 | A MEDICINAL AEROSOL FORMULATION | AEROPHARM TECHNOLOGY, INC. (US) | 2001-08-23 | — | — | WO | claimed |
| EP-0666729-A1 | COSMETIC COMPOSITION | UNILEVER PLC (GB) | 1995-08-16 | — | — | EP | claimed |
| WO-1994009750-A1 | COSMETIC COMPOSITION | UNILEVER PLC (GB) | 1994-05-11 | — | — | WO | claimed |
| US-5122515-A | Injecting dipeptide of tyrosine and arginine mixed with other nutrients | BAXTER INTERNATIONAL INC. | 1992-06-16 | — | — | US | claimed |
| EP-0457314-A1 | Nutrient compositions containing peptides | CLINTEC NUTRITION COMPANY (US) | 1991-11-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | BCR, TBCD, TBC1D5 | NPY4R 4623/4885NPY1R 4687/4885NPY5R 4476/4885 |
| US-20020110525-A1 | Modulated release particles for lung delivery | MUC1, CD44, CHMP4B | NPY4R 3130/4885NPY1R 2912/4885NPY5R 2188/4885 |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | SLC3A2, MTCL3, SLC13A2 | NPY4R 2467/4885NPY1R 1735/4885NPY5R 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.